Skip to main content

Change location

You are currently on the Mexico (Español) website

My country is not on the list

Global

  • Bracco.com (English)

Asia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Americas

  • Brazil (Português)
  • Canada (English)
  • Mexico (English)
  • Canada (Français)
  • USA (English)

Europe

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Careers
  • Media and News
  • Get in touch
    • Mexico (English)
  • Home
  • we are bracco
    We are Bracco

    Welcome to a World of contrasts

    • Our businesses
    • Purpose and values
    • Our history
    • Responsibility and Ethical conduct
  • Our Portfolio

    Proven offerings for a proven difference

    • X-ray/CT
      • Contrast agents

        • Sulfato de Bario
        • Bario TC
        • Radiologia/Fluoroscopia
        • Iomeron
        • Iopamiro
        • Cat-Bario
      • Medical devices

        • Empower CTA+
        • Accesorios Bario
    • MRI
      • Contrast agents

        • MultiHance
        • ProHance
      • Medical Devices

        • EmpowerMR
        • MustKit MR
    • Ultrasound
      • Contrast agents

        • Sonovue
    • Nuclear medicine
    • Interventional cardiology
      • Contrast agents

        • Iomeron
        • Iomeron 400
        • Iopamiro
      • Medical devices

        • ACIST CVi
    • Digital solutions
    • Oncology
    • Cardiology
  • Woman looking into microscope
    Innovation

    A deep dive into our R&D progress

    • Digital future
    • R&D
    • The Bracco sites
    • Scientific heritage and patents
  • knowledge
    Knowledge

    Current activities and future opportunities

    • E-learning
    • Partnerships in education
    • Events
  • Ceriano Laghetto
    Sustainability

    Our game plan and goals for a better world

    • Our sustainability pillars
    • Governance and transparency
    • Sustainability report
  • Our Stories
Page
Cardiology Despite the availability of effective therapies, ischaemic heart disease remains the leading cause of death around the world. Early and proper diagnosis is key to reducing cardiovascular mortality and diagnostic imaging plays a crucial role here.
A surgeon preparing for surgery.
Page
Oncology According to the World Health Organization (WHO), in 2020 cancer accounted for nearly 10 million deaths worldwide – that’s almost one in every six deaths – with cancers of the lung, colon, and rectum, and prostate being the most common.
Laboratory researcher is looking through a microscope.
Product
ProHance ProHance® (gadoteridol) es una molécula macrocìclica, no iônica, quelato del iòn gadolinio y tiene una muy baja osmolalidad y viscosidad5.
Bracco logo
Product
Multihance MultiHance® es un medio de contraste base gadolinio que tiene el doble de relaxividad que los medios de contraste extracelulares convencionales (EC), que le brinda un marcado incremento de la SNR (Relaciòn Señal Ruido) para una major visualizaciòn de lesiones pequeñas y mejorar la delineaciòn de grandes lesiones1.
Bracco logo
Product
EmpowerMR El Sistema de Inyecciòn de Medio de Contraste EmpowerMR® es un equipo de ùltima generaciòn integrado, diseñado para llenar las demandas de los procedimientos avanzados de RM hoy en dìa.
Bracco logo
Product
Sonovue SonoVue® fue aprobado por primera vez en la Unión Europea en el marco del procedimiento centralizado, el 26 de marzo de 2001 y se comercializa actualmente en 36 países en todo el mundo4.
Bracco logo
Product
ACIST CVi ACIST® Medical Systems, una empresa del Grupo Bracco, desarrolla tecnologías avanzadas de inyección de contraste que ayudan a simplificar las complejidades del laboratorio de cateterismo cardíaco.
Bracco logo
Article
BIPSO further strengthens environmental protection BIPSO sets the course for sterile contrast media production according to the latest environmental standards.
BIPSO production site
Article
FDA approves Gadopiclenol injection for the U.S. market Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY™ (gadopiclenol) injection and VUEWAY™ (gadopiclenol) Pharmacy Bulk Package by Bracco.
Vueway Gadopiclenol
Product
Bario TC E Z CAT Sulfato de Bario suspensión concentrada para tomografía axial computada Agítese bien antes de usar.
Bracco logo
  • Load More

The Bracco Group is an international group of highly specialized companies.
We are an active part of the healthcare sector, and a global leader in diagnostic imaging.

  • We are Bracco
  • Our Portfolio
  • Innovation
  • Knowledge
  • Sustainability
  • Our Stories
  • Farmacovigilancia/Tecnovigilancia
  • Data Protection

Connect with us

Via Egidio Folli 50
20134 Milan, Italy
Phone + 39 02 2177.1

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Imprint
  • for Bracco VPN users

Bracco Copyright © 2025 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182